Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limertinib plus bevacizumab versus limertinib alone as first-line treatment for EGFR-mutant, PD-L1-high non-squamous NSCLC
ChiCTR2500101370Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of limertinib and bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
limertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500101370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101370.